Gunjan Verma - India

“The new guidance applies to real time RTPCR, RAT, home based testing solutions, antigen/antibody ELISA/CLIA, and rapid antibody tests.”

Gunjan Verma
Managing Partner
Asia Actual India

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

India Exempts COVID Test Kits Approved in Reference Countries from Validation Testing

Published on: May 18th, 2021

COVID Test Kits Approved in the USA, EU, Korea, Japan, Australia, Brazil, or by WHO Are Now Exempt

As of April 27th, India’s CDSCO will allow COVID test kits with the following reference country approvals to bypass in-country validation testing. Previously only tests kits approved by the USFDA (including Emergency Use Authorization) were exempt.

COVID test kits approved by the following agencies are now exempt from in-country validation testing:

  1. United States Food and Drug Administration (USFDA)
  2. European CE/IVD
  3. Ministry of Food and Drug Safety of Korea (formerly known as Korea Food & Drug Administration or KFDA)
  4. Pharmaceuticals and Medical Devices Agency (PMDA) of Japan
  5. Therapeutic Goods Administration (TGA) of Australia
  6. Brazil’s ANVISA
  7. WHO’s Emergency Use Listing (EUL)

COVID Test Kits Applicable Products

The new guidance applies to real time RTPCR, RAT, home based testing solutions, antigen/antibody ELISA/CLIA, and rapid antibody tests. It is also applicable for tests using nasopharyngeal, oropharyngeal, throat, nasal, oral, saliva, mouth rinse, gargle, blood, and serum samples.

Regulatory Requirements in Addition to Validation

Once a COVID test kits has approved by the ICMR (or exempt via reference country approval), manufacturers will need to submit a full Device Master File (DMF). Regarding Plant Master Files (PMF) for new manufacturers, the CDSCO is currently accepting ISO 13485 certificates in lieu of typically required documentation. COVID test kits have also been up classified to Class C.

All manufacturers with point of care testing software will also need to meet with an ICMR team to ensure compatibility with the ICMR COVID-19 testing portal.

Come Grow with Us

Asia Actual assists medical device manufacturers navigate the regulatory requirements in Asia and build comprehensive regulatory and sales strategies for growing sales in the region.

Contact Asia Actual for more information or to discuss the region’s potential for your medical device or IVD.

Blog Posts

CDSCO Issues Updates to IVD Classification List in India

The Central Drugs Standard Control Organisation (CDSCO) of India issued a notice (PDF) on October 25, 2023 classifying in-vitro diagnostic (IVD) medical devices under medical device rules. The updates to IVD classification in India include intended use, associated risk, and other parameters.
Read more

Embracing Innovation and Collaboration: Highlights from the 15th CII Global MedTech Summit

On October 6, 2023, a team of enthusiastic members from the AAI (Artificial Intelligence and Innovation) group, including Ashoniya Puri, Sanjay Singh, and Rajat Budhori, had the honor of attending the prestigious 15th CII Global MedTech Summit. Hosted by the Confederation of Indian Industry (CII), one of India's largest industry bodies, this event brought together key players in the MedTech sector, both from India and abroad. The summit revolved around the central theme, "Paving the way for a USD 50 billion MedTech Industry by 2030," signifying a collective vision for the industry's future growth.
Read more

Bangladesh LAUNCHES NEW MEDICAL DEVICE REGULATIONS

On September 18, 2023, The Directorate General of Drug Administration (DGDA) published the Drug and Cosmetics Act 2023 formalizing the regulatory requirements of medical and diagnostic devices in Bangladesh with immediate effect.  A translated version of the document is available on Asia Actual’s website here.  All medical devices now require a Marketing Authorization Certificate to clear Customs and be sold on the market in Bangladesh.
Read more